ReviewApoptosis : an international journal on programmed cell death2025
Harnessing cuproptosis: a new avenue for targeted cancer therapies.
Review in Apoptosis : an international journal on programmed cell death, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Looking at the fraction with Annexin V⁺ and propidium iodide⁺: insights into cell death types from preclinical studies in solid and haematological cancers.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper-induced cell death, referred to as cuproptosis, introduces a new approach for cancer treatment by utilizing the toxic effects of copper. While copper is vital for enzymatic processes, it becomes harmful at excessive concentrations. Cuproptosis is characterized by mitochondrial impairment resulting from copper interacting with lipoylated components of the tricarboxylic acid (TCA) cycle, leading to proteotoxic stress and targeted cell death. This mechanism is distinct from traditional apoptosis and necrosis. Disruption of copper balance and associated genes, such as FDX1, LIAS, and DLAT, has been linked to various types of cancer. In this review, we outline the timeline of cuproptosis discovery and its comparison with other cell death mechanisms. In addition, we discuss copper homeostasis and copper metabolism in normal human physiology. We also reviewed how the disruption of copper balance can lead to cuproptosis and its involvement in tumorigenesis. Furthermore, we provided an overview of the various genes associated with cuproptosis and their roles in cancer. Given the numerous targets identified, we also provide a thorough overview of the drugs linked to cuproptosis and discuss their clinical relevance and prospects. This review indicates that targeting cuproptosis may serve as a novel therapeutic approach for cancer treatment.
Indexed as
Identifiers
40938523What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.